Novavax Starts COVID-19 Vaccine Trials On Children Aged Between 12-17 Years
World News | Agence France-Presse | Tuesday May 4, 2021
US biotech firm Novavax said Monday it had started clinical trials of its proposed Covid-19 vaccine on children, in a program that will involve up to 3,000 adolescents aged 12-17.
AstraZeneca, Novavax Ready To Scale Up COVID-19 Vaccine Production In Tie-Up With Serum Institute
India News | Press Trust of India | Thursday February 25, 2021
British-Swedish pharma giant AstraZeneca and US pharmaceutical major Novavax have told lawmakers that they are ready to scale up their production of COVID-19 vaccines in partnership with the Serum Institute of India.
India's Serum Institute Inks UN Deal For 1.1 Billion Covid Vaccines To 100 Countries
India News | Press Trust of India | Thursday February 4, 2021
The Serum Institute of India (SII) and UNICEF have entered into a long-term supply agreement for the AstraZeneca-Oxford 'Covishield' and the Novavax vaccines, with the UN children's agency saying it will have access to up to 1.1 billion doses of vaccines for around 100 countries.
Serum Institute To Supply 1.1 Billion Vaccine Doses For WHO-Led Covax Scheme: Top Official
India News | Reuters | Wednesday February 3, 2021
Serum Institute Of India will supply 1.1 billion doses of COVID-19 vaccines developed by AstraZeneca and Novavax to the COVAX vaccine scheme, as part of a new long-term deal, the head of the UN Children's Fund said on Wednesday.
"Hope To Launch Covovax By June 2021": Serum Institute's Adar Poonawalla
India News | Edited by Swati Bhasin | Saturday January 30, 2021
Serum Institute of India, the world's biggest vaccine maker, is hopeful of launching Covovax - developed in partnership with American vaccine developer Novavax - by June, its CEO Adar Poonawalla said today. The US-based pharma firm's Covid jab was found to be 89.3 per cent effective in a UK trial.
India Trial Sought for Novavax Covid Vaccine: 10 Facts
India News | Edited by Divyanshu Dutta Roy | Friday January 29, 2021
The Serum Institute of India, the world's biggest vaccine maker, has applied to local authorities to conduct a small domestic trial of American vaccine developer Novavax's COVID-19 jab, which was found to be 89.3 per cent effective in a UK trial. It was also found to be highly effective against a variant first identified in the UK. But the positive...
Novavax Claims Covid-19 Vaccine 89% Effective In UK Trial, Less In South Africa, Shares Jump
Business | Edited by Nirmalya Sen | Friday January 29, 2021
Serum Institute Of India has applied to conduct local trial for Novavax vaccine
Serum Institute Seeks India Trial Of A Second Covid Vaccine
India News | Reuters | Friday January 29, 2021
The Serum Institute of India, the world's biggest vaccine makers, has sought the drug regulator's permission to conduct a small domestic trial of the Novavax Inc COVID-19 vaccine that was found to be 89.3% effective in a UK trial, its CEO told Reuters on Friday.
Farmer Protest Latest News Live Updates: Rahul Gandhi Urges Farmers To Fight For Their Rights
India News | Edited by Aditi Ghosh, Arun Nair | Friday January 29, 2021
A tense situation prevailed at Delhi-Haryana border in Singhu after some people claiming to be "locals" threw stones at farmers protesting there and even tried to uproot their tents. The sudden violence at the protest site this afternoon, which has been tense, prompted the police to use tear gas shells and farmers to appeal for calm.
Novavax Covid Vaccine Highly Effective, But Not Against South Africa Variant
World News | Agence France-Presse | Friday January 29, 2021
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a variant first identified there.
Serum Institute To Stockpile Novavax Vaccine From April: Adar Poonawalla
India News | Reuters | Thursday January 14, 2021
The Serum Institute of India, the world's biggest vaccine maker, will start stockpiling millions of doses of the Novavax coronavirus vaccine candidate starting around April, CEO Adar Poonawalla told the Reuters Next conference on Thursday.
Phase 3 Trials Begin For Novavax Vaccine In US, Mexico
World News | Agence France-Presse | Tuesday December 29, 2020
Clinical trials to determine the safety and efficacy of a Covid-19 vaccine candidate from American biotech company Novavax have begun in the United States and Mexico, the US National Institutes of Health (NIH) announced Monday.
Produced 40 Million Doses Of AstraZeneca Covid Vaccine: Serum Institute
India News | Reuters | Thursday November 12, 2020
Serum Institute of India, the world's largest vaccine producer, said on Thursday it has made 40 million doses of AstraZeneca's potential COVID-19 vaccine, and would soon begin making Novavax's rival shot, as they both seek regulatory approval.
Novavax Delays US Trial Of COVID-19 Vaccine Candidate To November
World News | Reuters | Tuesday October 27, 2020
Novavax Inc on Tuesday delayed the start of a late-stage US trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.
US Firm Novavax Aims For 2 Billion COVID Vaccine Doses With Expanded India Deal
World News | Reuters | Tuesday September 15, 2020
US drug developer Novavax said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, sending its shares up about 7%.
Novavax Starts COVID-19 Vaccine Trials On Children Aged Between 12-17 Years
World News | Agence France-Presse | Tuesday May 4, 2021
US biotech firm Novavax said Monday it had started clinical trials of its proposed Covid-19 vaccine on children, in a program that will involve up to 3,000 adolescents aged 12-17.
AstraZeneca, Novavax Ready To Scale Up COVID-19 Vaccine Production In Tie-Up With Serum Institute
India News | Press Trust of India | Thursday February 25, 2021
British-Swedish pharma giant AstraZeneca and US pharmaceutical major Novavax have told lawmakers that they are ready to scale up their production of COVID-19 vaccines in partnership with the Serum Institute of India.
India's Serum Institute Inks UN Deal For 1.1 Billion Covid Vaccines To 100 Countries
India News | Press Trust of India | Thursday February 4, 2021
The Serum Institute of India (SII) and UNICEF have entered into a long-term supply agreement for the AstraZeneca-Oxford 'Covishield' and the Novavax vaccines, with the UN children's agency saying it will have access to up to 1.1 billion doses of vaccines for around 100 countries.
Serum Institute To Supply 1.1 Billion Vaccine Doses For WHO-Led Covax Scheme: Top Official
India News | Reuters | Wednesday February 3, 2021
Serum Institute Of India will supply 1.1 billion doses of COVID-19 vaccines developed by AstraZeneca and Novavax to the COVAX vaccine scheme, as part of a new long-term deal, the head of the UN Children's Fund said on Wednesday.
"Hope To Launch Covovax By June 2021": Serum Institute's Adar Poonawalla
India News | Edited by Swati Bhasin | Saturday January 30, 2021
Serum Institute of India, the world's biggest vaccine maker, is hopeful of launching Covovax - developed in partnership with American vaccine developer Novavax - by June, its CEO Adar Poonawalla said today. The US-based pharma firm's Covid jab was found to be 89.3 per cent effective in a UK trial.
India Trial Sought for Novavax Covid Vaccine: 10 Facts
India News | Edited by Divyanshu Dutta Roy | Friday January 29, 2021
The Serum Institute of India, the world's biggest vaccine maker, has applied to local authorities to conduct a small domestic trial of American vaccine developer Novavax's COVID-19 jab, which was found to be 89.3 per cent effective in a UK trial. It was also found to be highly effective against a variant first identified in the UK. But the positive...
Novavax Claims Covid-19 Vaccine 89% Effective In UK Trial, Less In South Africa, Shares Jump
Business | Edited by Nirmalya Sen | Friday January 29, 2021
Serum Institute Of India has applied to conduct local trial for Novavax vaccine
Serum Institute Seeks India Trial Of A Second Covid Vaccine
India News | Reuters | Friday January 29, 2021
The Serum Institute of India, the world's biggest vaccine makers, has sought the drug regulator's permission to conduct a small domestic trial of the Novavax Inc COVID-19 vaccine that was found to be 89.3% effective in a UK trial, its CEO told Reuters on Friday.
Farmer Protest Latest News Live Updates: Rahul Gandhi Urges Farmers To Fight For Their Rights
India News | Edited by Aditi Ghosh, Arun Nair | Friday January 29, 2021
A tense situation prevailed at Delhi-Haryana border in Singhu after some people claiming to be "locals" threw stones at farmers protesting there and even tried to uproot their tents. The sudden violence at the protest site this afternoon, which has been tense, prompted the police to use tear gas shells and farmers to appeal for calm.
Novavax Covid Vaccine Highly Effective, But Not Against South Africa Variant
World News | Agence France-Presse | Friday January 29, 2021
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a variant first identified there.
Serum Institute To Stockpile Novavax Vaccine From April: Adar Poonawalla
India News | Reuters | Thursday January 14, 2021
The Serum Institute of India, the world's biggest vaccine maker, will start stockpiling millions of doses of the Novavax coronavirus vaccine candidate starting around April, CEO Adar Poonawalla told the Reuters Next conference on Thursday.
Phase 3 Trials Begin For Novavax Vaccine In US, Mexico
World News | Agence France-Presse | Tuesday December 29, 2020
Clinical trials to determine the safety and efficacy of a Covid-19 vaccine candidate from American biotech company Novavax have begun in the United States and Mexico, the US National Institutes of Health (NIH) announced Monday.
Produced 40 Million Doses Of AstraZeneca Covid Vaccine: Serum Institute
India News | Reuters | Thursday November 12, 2020
Serum Institute of India, the world's largest vaccine producer, said on Thursday it has made 40 million doses of AstraZeneca's potential COVID-19 vaccine, and would soon begin making Novavax's rival shot, as they both seek regulatory approval.
Novavax Delays US Trial Of COVID-19 Vaccine Candidate To November
World News | Reuters | Tuesday October 27, 2020
Novavax Inc on Tuesday delayed the start of a late-stage US trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.
US Firm Novavax Aims For 2 Billion COVID Vaccine Doses With Expanded India Deal
World News | Reuters | Tuesday September 15, 2020
US drug developer Novavax said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, sending its shares up about 7%.
................................ Advertisement ................................
................................ Advertisement ................................
